Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GS 4104 neuraminidase inhibitor data

GILD and partner F. Hoffmann-La Roche Ltd. (Basel, Switzerland) presented statistically significant results of Phase II trials that tested the ability of an oral neuraminidase

Read the full 253 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE